Quantcast

Industry news that matters to you.  Learn more

Sarah Cannon and Genospace, LLC Announce Merger to Enhance Cancer Care Through Personalized Medicine Platform

Sarah Cannon, the Cancer Institute of Hospital Corporation of America (HCA), today announced that Genospace, LLC, a cloud-based software company focused on advancing personalized medicine, will merge with its organization and become a wholly-owned subsidiary. By joining forces, Sarah Cannon and Genospace will harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials.

Genospace Partner Sequence Bio Announces Initiative with Government of Newfoundland and Labrador on Large-Scale Precision Medicine Initiative

Genospace, a precision medicine software company that has developed a comprehensive suite of tools enabling the broad use of genomic and other biomedical data in research and clinical care, today announced that Sequence Bioinformatics, Inc. and the Government of Newfoundland and Labrador have selected Genospace Population Analytics™ to support a groundbreaking precision medicine initiative.

Thomson Reuters Reveals New Strategies for Navigating Big Data in the Pharmaceutical Industry

The IP & Science business of Thomson Reuters, the world’s leading provider of intelligent information for businesses and professionals, recently released Big Data and the Needs of the Pharma Industry, a whitepaper offering new strategies for managing Big Data, most specifically by using an array of technologies to convert it into more meaningful, accessible Little Data. The paper highlights how the inherently data-driven pharmaceutical industry requires deep, broad information to feed drug R&D, but the way it processes Big Data is unique.

Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition

GenoSpace, PathGroup and the IP & Science business of Thomson Reuters recently announced an innovative initiative to develop and deliver a best-in-class personalized medicine service in oncology, the result of which will enable physicians to make more precise therapeutic recommendations for cancer patients.

This partnership combines resources, technology and expertise across the three organizations to integrate PathGroup’s SmartGenomics™ Next Generation DNA Sequencing and Cytogenomic Array with traditional pathology assays, providing a unique window into disease and patient treatment options through genetic profiling.

“Collaboration is essential to deliver more precise medical solutions in today’s Big Data environment,” said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences. “Our coalition with GenoSpace and PathGroup leverages each organization’s unique assets, making significant improvements in treatment options for cancer patients.”

PathGroup’s industry-leading anatomic, clinical and molecular pathology services are integrated with the unparalleled information on genes, variants and therapeutic implications from Thomson Reuters. These are then overlaid with GenoSpace’s advanced analytical and information integration capabilities to place this diverse data into context. Oncologists will soon start receiving individualized reports that provide targeted information to help identify the best possible therapy for their patients.

“We have entered a new age of personalized medicine,” said Ben Davis, MD, Chairman, president and CEO of PathGroup. “It is one in which the unique genetic profile of each patient’s tumor, placed in the context of their disease, can help physicians select treatment options and improve outcomes. The GenoSpace and Thomson Reuters contributions to our SmartGenomics analyses add a highly sophisticated tool to our pathologist’s armamentarium in developing a patient genomic dossier.”

“One challenge in personalized medicine is assuring that what the physicians see is the most accurate and up-to-date information,” added Joseph Donahue, senior vice president of Thomson Reuters Life Sciences. “Thomson Reuters has always been focused on providing the most comprehensive information on genes and their functions, and we are delighted to be able to partner with PathGroup and GenoSpace to demonstrate how that information can be used to improve health care delivery.”

John Quackenbush, Ph.D., CEO of GenoSpace, said, “The GenoSpace FullView™ and GenoSpace for Clinical™ platforms integrate the vast pathology resources available at PathGroup with sequence and array data and information, tying in the extensive knowledgebase available through Thomson Reuters, to deliver concise, relevant and actionable reports to oncologists in a format that they find useful in making treatment decisions. By bringing together the complementary strengths of each company, we will be able to deliver a market-leading solution in personalized genomic medicine.”

Source: Thomson Reuters